Fig. 6.

In vivo efficacy of CAR T cell treatment in OS tumors. A Schematic illustration of in vivo experimental design. PBS (blue) or 100 μg mAb anti-B7-H3-FITC mAb (red) is administrated by intraperitoneal injection (IP) (D-1) to NSG mice-bearing 143B tumors. Next day (D0), intravenous injection of PBS (light blue = A, light red = B) or 5 × 10⁶ CAR T cells (dark blue = C, dark red = D) is performed (IV). PBS or anti-B7-H3-FITC mAb (50 μg; red arrows) is administrated every 3–4 days. Legend on the right indicates the different conditions. B Follow-up of tumor growth in mice treated with different conditions represented as mean + SEM (left) and individual values (right). *, P < 0.05 by one-way ANOVA with Tukey post hoc test. C Graphs on the left represent the individual areas under the curve (AUC) calculated from tumor growth of mice treated with different conditions. Little graph on the right upper corner represents the AUC expressed as mean + SD. *, P < 0.05 by one-way ANOVA with Tukey post hoc test. D Graph shows antitumor activity mean + SD of different condition related to PBS + PBS (A) group. **, P < 0.01 by one-way ANOVA with Tukey post hoc test